Literature DB >> 34937912

Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism.

Zhenmei Xu1, Tatsuya Ikuta2, Kouki Kawakami2, Ryoji Kise2, Yu Qian1, Ruixue Xia1, Ming-Xia Sun3, Anqi Zhang4, Changyou Guo4, Xue-Hui Cai3, Zhiwei Huang5, Asuka Inoue6, Yuanzheng He7.   

Abstract

Sphingosine-1-phosphate receptor 1 (S1PR1) is a master regulator of lymphocyte egress from the lymph node and an established drug target for multiple sclerosis (MS). Mechanistically, therapeutic S1PR1 modulators activate the receptor yet induce sustained internalization through a potent association with β-arrestin. However, a structural basis of biased agonism remains elusive. Here, we report the cryo-electron microscopy (cryo-EM) structures of Gi-bound S1PR1 in complex with S1P, fingolimod-phosphate (FTY720-P) and siponimod (BAF312). In combination with functional assays and molecular dynamics (MD) studies, we reveal that the β-arrestin-biased ligands direct a distinct activation path in S1PR1 through the extensive interplay between the PIF and the NPxxY motifs. Specifically, the intermediate flipping of W2696.48 and the retained interaction between F2656.44 and N3077.49 are the key features of the β-arrestin bias. We further identify ligand-receptor interactions accounting for the S1PR subtype specificity of BAF312. These structural insights provide a rational basis for designing novel signaling-biased S1PR modulators.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34937912     DOI: 10.1038/s41589-021-00930-3

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   16.174


  49 in total

Review 1.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

2.  Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.

Authors:  Myat Lin Oo; Shobha Thangada; Ming-Tao Wu; Catherine H Liu; Timothy L Macdonald; Kevin R Lynch; Chen-Yong Lin; Timothy Hla
Journal:  J Biol Chem       Date:  2007-01-21       Impact factor: 5.157

3.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

4.  Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization.

Authors:  David A Sykes; Darren M Riddy; Craig Stamp; Michelle E Bradley; Neil McGuiness; Afrah Sattikar; Danilo Guerini; Ines Rodrigues; Albrecht Glaenzel; Mark R Dowling; Florian Mullershausen; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

Review 5.  Sphingosine-1-phosphate receptors and innate immunity.

Authors:  Arielle M Bryan; Maurizio Del Poeta
Journal:  Cell Microbiol       Date:  2018-03-23       Impact factor: 3.715

6.  Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets.

Authors:  Thiet M Vu; Ayako-Nakamura Ishizu; Juat Chin Foo; Xiu Ru Toh; Fangyu Zhang; Ding Ming Whee; Federico Torta; Amaury Cazenave-Gassiot; Takayoshi Matsumura; Sangho Kim; Sue-Anne E S Toh; Toshio Suda; David L Silver; Markus R Wenk; Long N Nguyen
Journal:  Nature       Date:  2017-10-18       Impact factor: 49.962

7.  The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors.

Authors:  Atsuo Kawahara; Tsuyoshi Nishi; Yu Hisano; Hajime Fukui; Akihito Yamaguchi; Naoki Mochizuki
Journal:  Science       Date:  2008-12-11       Impact factor: 47.728

8.  Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.

Authors:  Akira Murakami; Hiroshi Takasugi; Shinya Ohnuma; Yuuki Koide; Atsuko Sakurai; Satoshi Takeda; Takeshi Hasegawa; Jun Sasamori; Takashi Konno; Kenji Hayashi; Yoshiaki Watanabe; Koji Mori; Yoshimichi Sato; Atsuo Takahashi; Naoki Mochizuki; Nobuyuki Takakura
Journal:  Mol Pharmacol       Date:  2010-01-22       Impact factor: 4.436

9.  Sphingosine-1-phosphate: From insipid lipid to a key regulator.

Authors:  Sarah Spiegel
Journal:  J Biol Chem       Date:  2020-03-06       Impact factor: 5.157

10.  Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2020-10-27       Impact factor: 5.749

View more
  4 in total

Review 1.  Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling.

Authors:  Mohammad Seyedabadi; Mehdi Gharghabi; Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Trends Biochem Sci       Date:  2022-04-05       Impact factor: 14.264

2.  Structural basis for receptor selectivity and inverse agonism in S1P5 receptors.

Authors:  Elizaveta Lyapina; Egor Marin; Anastasiia Gusach; Philipp Orekhov; Andrey Gerasimov; Aleksandra Luginina; Daniil Vakhrameev; Margarita Ergasheva; Margarita Kovaleva; Georgii Khusainov; Polina Khorn; Mikhail Shevtsov; Kirill Kovalev; Sergey Bukhdruker; Ivan Okhrimenko; Petr Popov; Hao Hu; Uwe Weierstall; Wei Liu; Yunje Cho; Ivan Gushchin; Andrey Rogachev; Gleb Bourenkov; Sehan Park; Gisu Park; Hyo Jung Hyun; Jaehyun Park; Valentin Gordeliy; Valentin Borshchevskiy; Alexey Mishin; Vadim Cherezov
Journal:  Nat Commun       Date:  2022-08-12       Impact factor: 17.694

3.  Structure of the active Gi-coupled human lysophosphatidic acid receptor 1 complexed with a potent agonist.

Authors:  Hiroaki Akasaka; Tatsuki Tanaka; Fumiya K Sano; Yuma Matsuzaki; Wataru Shihoya; Osamu Nureki
Journal:  Nat Commun       Date:  2022-09-15       Impact factor: 17.694

4.  Structural basis of adhesion GPCR GPR110 activation by stalk peptide and G-proteins coupling.

Authors:  Xinyan Zhu; Yu Qian; Xiaowan Li; Zhenmei Xu; Ruixue Xia; Na Wang; Jiale Liang; Han Yin; Anqi Zhang; Changyou Guo; Guangfu Wang; Yuanzheng He
Journal:  Nat Commun       Date:  2022-09-20       Impact factor: 17.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.